- Home
- WLY vs MRUS Comparison
WLY vs MRUS Comparison
Compare WLY & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- MRUS
- Stock Information
- Founded
- WLY 1807
- MRUS 2003
- Country
- WLY United States
- MRUS Netherlands
- Employees
- WLY N/A
- MRUS N/A
- Industry
- WLY Books
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- WLY Consumer Discretionary
- MRUS Health Care
- Exchange
- WLY Nasdaq
- MRUS Nasdaq
- Market Cap
- WLY 2.7B
- MRUS 2.9B
- IPO Year
- WLY N/A
- MRUS 2016
- Fundamental
- Price
- WLY $44.38
- MRUS $41.85
- Analyst Decision
- WLY
- MRUS Strong Buy
- Analyst Count
- WLY 0
- MRUS 12
- Target Price
- WLY N/A
- MRUS $87.92
- AVG Volume (30 Days)
- WLY 467.4K
- MRUS 670.1K
- Earning Date
- WLY 12-05-2024
- MRUS 10-31-2024
- Dividend Yield
- WLY 3.18%
- MRUS N/A
- EPS Growth
- WLY N/A
- MRUS N/A
- EPS
- WLY N/A
- MRUS N/A
- Revenue
- WLY $1,759,570,000.00
- MRUS $35,932,000.00
- Revenue This Year
- WLY N/A
- MRUS N/A
- Revenue Next Year
- WLY $1.12
- MRUS $57.37
- P/E Ratio
- WLY N/A
- MRUS N/A
- Revenue Growth
- WLY N/A
- MRUS N/A
- 52 Week Low
- WLY $30.45
- MRUS $26.69
- 52 Week High
- WLY $53.96
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- WLY 26.68
- MRUS 39.11
- Support Level
- WLY $43.93
- MRUS $41.03
- Resistance Level
- WLY $46.15
- MRUS $45.25
- Average True Range (ATR)
- WLY 1.28
- MRUS 2.21
- MACD
- WLY -0.35
- MRUS 0.02
- Stochastic Oscillator
- WLY 6.34
- MRUS 10.15
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.